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Objectives:
 
 This paper presents an economic evaluation
of a strategy of thromboprophylaxis in acutely ill medi-
cal patients with enoxaparin 40 mg vs. no intervention
in the context of the French Health System.
 
Methods:
 
 The evaluation used a decision-analysis model
to simulate the results of a hypothetical naturalistic,
long-term study reflecting the usual care pattern for the
patients. The short-term outcomes were derived from an
international, double-blind, placebo-controlled random-
ized clinical study performed in 1102 patients older than
 
40 years. Treatment was scheduled to last 10 
 

 
 4 days
and primary outcome was venous thromboembolism
events rates between days 1 and 14 assessed clinically or
through systematic contrast venography.
 
Results:
 
 For an hypothetical cohort of 1000 hospital-
ized medical patients, the model suggested that the pro-
phylaxis strategy would avoid between 1 and 10 deaths
(median 4) and between 60 and 127 cases of venous
thromboembolism events (median 94). By including or
not the costs associated with long-term complications
(post–phlebitis syndrome), the net extra cost per patient
 
was estimated as a net saving or 35,857 Euros (
 
€
 
), re-
spectively. The corresponding cost-effectiveness ratios
in terms of cost per avoided death were a net saving or
 
€
 
8102 (median value), respectively.
 
Conclusions:
 
 Thromboprophylaxis with enoxaparin in
hospitalized acutely ill patients over 40 years of age ap-
pears to be an efficient strategy using French cost data.
 
Keywords:
 
 cost-effectiveness analysis, LMWH, preven-
tion, venous thromboembolism.
 
Introduction
 
Low-molecular weight heparin (LMWH) has been
shown to be effective in the prophylaxis of venous
thromboembolic disease in surgical patients [1,2].
The cost-effectiveness of perioperative thrombo-
prophylaxis with LMWH in surgical patients has
also been extensively studied and positive conclu-
sions have been drawn on this topic [3]. Neverthe-
less, most cases of fatal pulmonary embolism oc-
cur in nonsurgical patients [4,5]. Evidence of the
benefits of thromboembolic prophylaxis in such
populations so far remains limited. In certain groups
of medical patients considered to be at high risk
(e.g., those of advanced age, or with stroke, myo-
cardial infarction, or prolonged immobility), the
use of a thromboprophylaxis is recommended [6,7].
For other medical patients, the situation remains
controversial. However, the recent publication of
several randomized studies has improved our knowl-
edge of the clinical benefit that could be expected
from systematic thromboprophylaxis in bedridden
patients with medical illnesses [8–11].
The present economic evaluation is based on
the results of one of these studies, the MEDENOX
trial [11], a double-blind, placebo-controlled, ran-
domized trial comparing enoxaparin vs. placebo
in acutely ill medical patients over 40 years of age.
As mentioned in other similar approaches, a series
of methodological hurdles are present in this do-
main. The most important is that diagnosis meth-
ods used in clinical trials to assess the outcomes of
thromboprophylaxis (mandatory venography or
ultrasonography) are not used in routine practice.
Moreover, the time frame of clinical trials is only
short-term and such a perspective is not relevant
for an economic evaluation that must include long-
term consequences of the strategy used.
Long-term naturalistic trials are not feasible con-
sidering practical issues (sample size, costs, etc.).
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For these reasons, cost-effectiveness studies in this
domain often use modeling techniques. In the pres-
ent study, we have analyzed the cost-effectiveness
of thromboprophylaxis in medical patients in the
French context, using a decision-tree model and
multiway sensitivity analyses.
 
Methods
 
Clinical Data
 
MEDENOX, an international multicenter double-
blind, placebo-controlled, randomized study was
carried out to determine the frequency of venous
thromboembolism and the efficacy and safety of
routine prophylaxis in hospitalized patients with
acute medical illnesses. Details of the study have
been published elsewhere [11]. In brief, 1102 hos-
pitalized medical patients older than 40 years were
randomly assigned to receive 20 mg of enoxaparin,
40 mg of enoxaparin or placebo subcutaneously once
daily. To be eligible, patients had to have at least one
of the following additional risk factors for venous
thromboembolism: congestive heart failure (NYHA
class III or IV), acute respiratory failure, acute infec-
tion, rheumatic disorder, or an episode of inflam-
matory bowel disease. The study was carried out in
61 centers located throughout 9 countries (mainly
France, United Kingdom, and Canada). Treatment
was scheduled to last 10 
 

 
 4 days and patient fol-
low-up 90 
 

 
 15 days. The primary outcome with
respect to efficacy was the number of venous throm-
boembolism episodes (deep-vein thrombosis (DVT)
and/or pulmonary embolism (PE)) clinically identi-
fied between day 1 and day 10 
 

 
 4. The incidence
of adverse events and abnormal laboratory findings
were also assessed throughout the study.
The primary outcome could finally be assessed in
866 patients. The incidence of venous thromboem-
bolism events was significantly lower in the group
of patients who received 40 mg of enoxaparin than
in the placebo group (5.5% and 14.9%, respec-
tively; relative risk 
 

 
 0.37, 
 
P
 
 
 

 
 .001). There was no
significant difference between the group who had
received 20 mg enoxaparin and the placebo group.
The benefit observed with 40 mg enoxaparin was
maintained at three months. The incidence of ad-
verse events was not statistically different between
the placebo and the two enoxaparin groups.
 
Study Model
 
A decision analysis model originally developed by
Oster et al. [12,13] and used in various economic
evaluations in the field of venous thromboembo-
lism prophylaxis [14–18] was adapted to simulate
a hypothetical naturalistic study incorporating the
main results of the reference trial but differing from
them with regards to the following aspects: 1) diag-
nostic tests routinely used for patient management
in France as opposed to the mandatory first-line
venography or ultrasonography tests used in the
trial; 2) long-term efficacy criteria (death rate and
life-years gained) extrapolated from intermediate
health outcomes (venous thromboembolism events)
using known natural history of venous thromboem-
bolism; 3) direct costs of thromboembolism compli-
cations, hemorrhagic events, and diagnostic tests as-
sessed according to standard medical practice in
France. This model is illustrated by a decision tree
(Fig. 1). Its objective is to reflect the consequences of
enoxaparin prophylaxis vs. placebo for hospitalized
medical patients in the real world rather than in a
clinical trial context. Since the study showed no sig-
nificant difference between 20 mg enoxaparin and
placebo, the economic evaluation was restricted to a
40-mg enoxaparin vs. placebo comparison.
The model only considered the primary outcome
of the study: events resulting from venous throm-
boembolism that occurred during the treatment pe-
riod (i.e., 10 
 

 
 4 days) and thus did not consider
events that may have occurred later. Very few
venous thromboembolic events were clinically iden-
tified during the follow-up period (2 events among
263 patients in the placebo group and 3 events
among 272 patients in the 40 mg enoxaparin group).
The first node of the decision tree reflects the in-
cidence of DVT (by type of treatment) that could be
detected if all patients underwent venography or ul-
trasonography. Obviously, all these incident cases
would not be clinically detectable and, conversely,
some patients would have clinical symptoms with-
out underlying venous thromboembolism. The sub-
sequent branches reflect patient status regarding
DVT tests and related outcomes: true-positives, true
and false-negatives (based on test performance). In
contrast to previous studies based on the same mod-
eling approach, it was considered that all DVT
symptoms that occurred in acutely ill medical pa-
tients are not systematically investigated in real prac-
tice. The decision tree also considers potential migra-
tion of thrombus (Fig. 1b: subtree), probability of PE
diagnostic investigations, and consequences of DVT
and PE treatments. The model assumed all PE to be
consequences of undiagnosed and untreated venous
thrombosis. Because reliable data is lacking, long-
term morbidity associated with venous thrombo-
embolism (i.e., post–phlebitic syndrome) was only
addressed in terms of associated costs.
Finally, the tree ends up, for each of the two treat-
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Figure 1 (a) Main decision-tree model. All probabilities are published mean values [13–16]. Circles indicate chance nodes.
(DVT, deep vein thrombosis; PE, pulmonary embolism). (b) PE Sub-tree. All probabilities are published mean values [13–16].
Circles indicate chance nodes. (DVT, deep vein thrombosis; PE, pulmonary embolism).
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ment scenarios, with 38 branches which ultimately
end with a dead/alive chance node. The model was
developed using Data® software (TreeAge Soft-
ware, Williamstown, MA).
 
Probabilities and Cost Inputs
 
Three different types of parameters were consid-
ered: the initial parameters (i.e., DVT rates di-
rectly derived from the clinical trial), the interme-
diary and final parameters allowing progression
along the tree until the end node, and costs param-
eters associated with diagnostic procedures and
treatments. As available data could not guarantee
an accurate estimate for most parameters used in
the model, we used a Monte Carlo simulation
technique that consisted of assigning to each pa-
rameter a distribution of possible values. A com-
puterized program then generates simultaneously
random numbers for each parameter, according to
the predefined distributions. Thereafter, the model
successively computes each set of parameters to
produce distributions of the results. In total, 1000
sortings were generated in this way.
 
Initial Parameters.
 
The DVT rates of the enox-
aparin and placebo treatment groups are based on
the primary outcomes of the reference trial. The
main finding of this trial was to demonstrate a sig-
nificant statistical difference in the rates of throm-
boembolism rates between patients who received
40 mg of enoxaparin and those who did not.
Rates, however, can only be interpreted as specific
results obtained in a clinical trial context. Because
the trial does not tell us what these figures are in
the real world, we decided to take this uncertainty
into account by building distributions of pairs val-
ues by drawing lots following normal distribu-
tions for the two arms (enoxaparin and placebo).
Observed rates in the trial were used as mean val-
ues and the 95% confidence interval divided by
1.96 as standard deviation of the distribution. Fi-
nally, when pairs of values did not result in a sta-
tistically significant difference between two rates,
using for this calculation trial enrollment figures,
they were excluded from the analysis. This step
was conducted simultaneously and independently
of the intermediary probability randomization.
 
Intermediary Probabilities.
 
Due to the lack of data
concerning hospitalized medical patients, we as-
sume that natural history of thromboembolic events
is not driven by the patient’s initial condition. Sev-
eral pharmacoeconomic studies provided estimates
on potential evolutions of thromboembolic events
in surgical patients [13–16]. The intermediary esti-
mates in the decision tree (Fig. 1) are the means of
these estimates. If this mean was 0 or 1, probabil-
ity was considered to be certain. Conversely, if
this mean was strictly between 0 and 1, we built
normal distributions by drawing lots assuming the
following general probabilistic rules: 1) the mean
of other published estimates corresponds to the
mathematical expectancy of a normal distribution
reflecting all possible values for this intermediary
probability; 2) uncertainty of a probability close
to 0 or 1 is lower than of a probability close to 0.5
and standard deviations must be defined accord-
ingly: therefore, we applied a standard deviation
equal to 50% of the mean when this value was
lower than 0.5 and equal to 0.5 minus 50% of the
mean when greater than 0.5; 3) the resulting prob-
abilities which were out of the range between 0
and 1 were excluded.
 
Cost Parameters.
 
The economic study was con-
ducted from a societal perspective. Nevertheless, in-
direct costs (i.e., productivity losses due to absen-
teeism from work) were not considered because of
the older age of the patients. We also did not take
into account costs of adverse events since the clini-
cal trial had not shown any difference between the
two treatments. Because clinical surveillance of
patients was assumed to be the same in the two
arms, associated costs were also excluded from the
analysis. Finally, six cost parameters were consid-
ered in the model (Table 1). All costs were calcu-
lated for the year 1998 and expressed in Euros (
 
€
 
).
Due to the lack of published data we organized
a survey among: 1) a sample of 50 hospital-based
specialists (mainly from internal medicine and ge-
riatric wards) to describe diagnostic practices in
view of clinical suspicion of thrombosis in hospi-
talized medical patients; and 2) 50 general practi-
tioners (GPs) to gather information about medical
management of patients after an in-patient epi-
sode of thrombosis.
The survey showed that, facing a clinical suspi-
cion of distal DVT, hospital specialists performed
ultrasound examination in 100% of patients and
an ELISA plasma d-dimer assay in 20%. When
suspecting proximal DVT, specialists also system-
atically prescribed ultrasonography, a contrast ve-
nography in 20% of patients, and a plasma d-dimer
dosage in 10%. For PE diagnosis in symptomatic
patients, several tests were performed which re-
quired approximately the full cost of 1.5 hospi-
talization days. Unitary costs of diagnostic tests
were derived from the French National Diagnostic-
Related Group Cost Study [19,20], as were DVT
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and PE treatment costs. These are fully loaded
costs estimated from analytical accounting on a
national sample of French hospitals.
According to the survey, GPs hospitalize 10%
of ambulatory patients with distal deep-venous
thrombosis. The remaining patients receive a 10-
day curative LMWH treatment, followed by an
oral anticoagulant treatment for 90 days. In the
case of proximal DVT, 70% of patients are hospi-
talized and the remaining 30% receive a 14-day
LMWH treatment followed by a 90-days oral an-
ticoagulant treatment. Finally, all symptomatic
PEs are hospitalized. The unitary costs of these
visits, injections, laboratory tests, and examina-
tions were based on current tariffs, as determined
by the French National Sickness Fund [21].
We assumed that post–phlebitis syndrome treat-
ment costs on average corresponded to two thirds
of initial DVT treatment costs, as observed in the
main economic study published on this topic [22].
This cost was applied to every patient surviving
initial DVT. Since the proportion of two thirds
was established in a different setting (i.e., younger
age, and in Sweden), a second set of calculations
was conducted without the costs of post–phlebitis
syndromes.
For the enoxaparin prophylactic treatment costs,
our estimate included the hospital list price in
France of a prefilled syringe of 40 mg of enoxaparin
(i.e., 
 
€
 
5.45), the cost of subcutaneous injections ad-
ministered by a private nurse, using the value given
in a recent microcosting evaluation [23], and the
cost of one platelet count per week (i.e., 
 
€
 
9.68 each
[21]). Nevertheless, it should be noted that the
prefilled syringe tariff might overestimate the real
cost since most hospitals negotiate rebates with
the manufacturers.
As for the intermediate parameters, we ad-
dressed the uncertainty of cost estimates by simu-
lation techniques, based this time on a uniform
function, considering a 50–150% interval around
these estimates. Because our estimate of enoxa-
parin treatment costs probably has overestimated
real costs, we did not vary that specific parameter,
adopting in that way a worst case-scenario ap-
proach.
 
Efficacy Criteria
 
Incremental change in mortality between the two
treatment groups was defined as the main efficacy
criterion. To allow comparison with other pub-
lished cost-effectiveness ratios, avoided deaths were
transformed into life-years gained. French life ta-
bles indicate that life expectancy at 73.5 years
(i.e., mean age in the reference trial) is 10.5 years
in males and 13.5 years in females. However, hos-
pitalized patients with acute medical illnesses prob-
ably have a lower life expectancy than in the gen-
eral population. In the absence of specific survival
data, we considered two life expectancy scenarios
in our model: 6 years (twice less than the general
population) and 3 years (four times less). Two sec-
ondary efficacy criteria were produced by the
model, i.e., the number of cases of venous throm-
boembolism events avoided per 1000 patients and
the number of cases of symptomatic (i.e., diag-
nosed and treated) venous thromboembolism
events avoided per 1000 patients. Due to the utili-
zation of the Monte Carlo methodology, the
model generates distributions of results. Each one
was further characterized by the median and the
fifth and 95th percentiles.
 
Results
 
Results were calculated for a hypothetical cohort
of 1000 acutely ill medical patients in each arm.
 
Deaths and DVT Avoided
 
Administration of 40 mg of enoxaparin during 10
days in 1000 individuals would avoid between 1
and 10 deaths (median 4 deaths), according to our
simulations (Table 2). The total number of cases
of venous thromboembolism events that could
have been prevented according to the reference
trial is 94, i.e., if contrast venography (or ultra-
sonography) was systematically performed after
10 days. In current practice, the simulations show
that the median number of clinically detected
cases of thromboembolism events avoided would
be approximately 16.
 
Incremental Direct Costs
 
If the costs of post–phlebitis syndrome are in-
cluded, prophylactic enoxaparin treatment is likely
to produce net savings (Table 2). Even if we con-
sider extreme values (i.e., 95th percentile), net cost
per patient treated would be 
 
€
 
4012 only. When
 
Table 1
 
Costs parameters (1998 Euros; 
 
€
 
) 
 
used in
the model
 
Parameter Baseline Estimate
Confirming clinical suspicion of DVT 70
Confirming clinical suspicion of PE 568
Treatment of DVT 1,453
Treatment of PE 5,188
Treatment of post-phlebitis syndromes 0-981
10 days enoxaparin treatment (in-patient) 66
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post–phlebitis syndromes are excluded, then net
cost per treated patient ranges between 
 
€
 
957 and
 
€
 
52,914, with a median value of 
 
€
 
35,857.
 
Cost-effectiveness Ratios
 
We calculated two different cost-effectiveness ratios,
i.e., cost per death avoided and cost per life-year
saved. Results are shown in Table 2. When con-
sidering post–phlebitis syndrome costs, the 10-day
enoxaparin treatment appears to be both more ef-
fective and less expensive (or only slightly more
costly) than placebo. When post–phlebitis syndrome
costs are excluded, the cost per death avoided ra-
tio are established at 
 
€
 
8102 (median of results).
These ratios were further transformed into costs
per life-year saved using two different life-expect-
ancy scenarios for hospitalized medical patients.
Assuming a worst case scenario (life expectancy 3
years, 95th percentile), the cost per life-year saved
would not exceed 17,757. If we consider a more
realistic but still conservative scenario (life expect-
ancy 3 years, median), the cost per life-saved ratio
would be only 2701.
 
Sensitivity Analysis
 
Since uncertainty is already directly addressed by
the model, the sensitivity analysis was conducted
with the objective of identifying parameters that
have the largest impact on results rather than test-
ing the strength of the results with regard to the
base assumptions. The incremental cost of treat-
ment (40 mg of enoxaparin vs. placebo) was par-
ticularly sensitive (in decreasing order) to post-
phlebitis costs, DVT rates in the two branches of
the decision tree, and costs of enoxaparin prophy-
laxis. It should be remembered that this last pa-
rameter was defined on a very conservative basis,
i.e., by using official tariffs rather than current
prices that include rebates.
If we consider the number of deaths avoided (or
life-years saved), the results appear to be sensitive
in decreasing order to the following parameters:
DVT rates in both branches, incidence of PE among
asymptomatic DVT patients, and mortality rate
among patients having survived the first hours of
an asymptomatic PE.
 
Discussion
 
Concerning the results of the reference trial, the
prophylaxis utilization of enoxaparin 40 mg, for
10 days in hospitalized medical patients was shown
to be clearly beneficial compared to placebo. The
economic evaluation extrapolated from these clini-
cal results in the context of the French health care
system also provides a positive response in terms of
the efficiency of this strategy. The extra costs of
prophylaxis appeared to be rather low compared to
the expected benefits, even in the case of the most
unfavorable assumptions. The cost per life-year
gained ratio remains inferior to 
 
€
 
2701 by using the
median of the distribution of this parameter.
Taking into account the possible long-term com-
plications (post–phlebitic syndromes), the strategy
appeared even dominant (economic benefit). The
relatively high variance of the distributions ob-
tained through the simulation is explained by the
uncertainty associated with the natural history of
venous thromboembolic disease, and with usual
care pattern associated costs.
 
Table 2
 
Incremental outcomes, costs, and cost-effectiveness with enoxaparin treatment (vs. placebo)
 
Variable 5th centile Median 95th centile
Outcomes, no. of cases avoided per 1,000 patients
Death 0.8 4.2 10.7
All DVT and PE 60.2 94.0 127.4
Symptomatic DVT and PE 6.1 15.6 0.9
Incremental net cost per 1,000 patients (
 
€
 
)
With post-phlebitis syndrome Net saving Net saving 4,012
Without post-phlebitis syndrome 957 35,857 52,914
Cost-effectiveness (
 
€
 
)
With post-phlebitis syndrome:
Cost per death avoided Net saving Net saving 1,123
Cost per life-year gained
Life expectancy 6 years Net saving Net saving 187
Life expectancy 3 years Net saving Net saving 374
Without post-phlebitis syndrome:
Cost per death avoided 208 8,102 53,270
Cost per life-year gained
Life expectancy 6 years 35 1,350 8,878
Life expectancy 3 years 70 2,701 17,757
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These results obtained for hospitalized medical
patients can be compared to the corresponding
values calculated for surgical patients, especially
after total hip replacement surgery comparing enox-
aparin with heparin or warfarin. Menzin [16] esti-
mated at US $12,300 per death avoided the cost-
effectiveness ratio in this last indication. O’Brien [14]
provided a value of US $2077. The corresponding
value found here was US $7600 (
 
€
 
8102) in our high-
est estimation not including long-term complications
(post–phlebitis syndrome). This result is also of the
same order of magnitude as the incremental cost-
effectiveness ratios obtained in a previous study done
in the same national context and comparing pro-
longed vs. short-term prophylaxis after total hip
replacement [17]. Finally, the median cost per life-
year gained ratio of enoxaparin prophylaxis vs.
placebo in acutely ill medical patients is lower
than those reported for other routinely used health
care procedures in France (i.e., hemodialysis [24]).
In the model, we considered these uncertainties
by choosing a series of conservative hypotheses.
The 95% range of our cost-effectiveness ratio is
between 
 
€
 
0 and 
 
€
 
13,568, which remains largely
inferior to the generally accepted threshold value of
60,000–75,000 per life-year gained (Fig. 2). The
sensitivity analysis that we performed did not show
strong relationships between the cost-effectiveness
ratio calculated and any parameters. Only 4 vari-
ables appeared with moderate significance, i.e.,
the differential rate of DVT between treatment
and placebo, treatment cost, the risk of further PE
among patients with DVT, the death rate in pa-
tients presenting with a non-diagnosed PE and
surviving for at least one hour.
The results presented here were established by
using only the outcomes of the clinical study mea-
sured on day 10 
 

 
 4. In the trial, the patients were
followed for an extra 80 days. During this addi-
tional follow-up period, no significant difference
was observed between the two arms. Therefore,
the results would not have been modified if we
had taken into account this long-term follow-up.
However, it should be noted that the results ob-
tained are applicable only to in-patient care. The
extension of these results to bedridden patients at
home would imply a series of further assumptions
or changes:
• Similarity of clinical and demographic charac-
teristics of patients treated at home and in hos-
pitals;
• Specificity of usual care for out-patients (for
example, in diagnosis procedures);
• Modification of some unit cost items.
Another remark can be made concerning the
duration of thromboprophylaxis of 6–14 days.
This duration was chosen in order to match the
usual duration of hospitalization among medical
patients. The appropriateness of prolonging pro-
phylaxis in patients staying longer or presenting
with high risk for thromboembolism should be in-
vestigated in the future.
Finally, our results are based on data of a major
recent clinical trial comparing LMWH with pla-
cebo. A recent meta-analysis of randomized clini-
cal trials concluded that unfractionated heparins
were beneficial in the prevention of venous throm-
boembolism in internal medicine [25]. Therefore,
it would be interesting to repeat a cost-effective-
ness analysis comparing this time LMWH with
unfractionated heparin.
 
Conclusions
 
Despite the usual uncertainties that characterize
economic evaluations in the domain of venous
thromboembolic disease, this study provides good
evidence for the efficiency of LMWH (enoxaparin)
anticoagulant prophylaxis administered 6–14 days
during the stay of acutely ill medical patients over
40 years of age in hospitals.
The incremental cost-effectiveness ratios ob-
tained with this strategy (vs. placebo) compare fa-
vorably with those of other health care procedures
used in the same national context. Further clinical
and economic studies are needed to validate these
results in the case of bedridden patients cared for
at home.
Figure 2 Incremental cost-effectiveness ratio of enoxaparin
prophylaxis (vs. placebo) among acutely ill medical patient
compared with those of hemodialysis [24] in France. *Results
obtained assuming a worst case scenario (i.e., without costs
of post–phlebitis syndromes and life expectancy of 3 years
only).
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